Rechercher des projets européens

32 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system (NEUROPAIN)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous inv ...
Voir le projet

 12

 TERMINÉ 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Voir le projet

 27

 TERMINÉ 

Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (Neuromics)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Neurodegenerative (ND) and neuromuscular (NM) disease is one of the most frequent classes of rare diseases, affecting life and mobility of 500,000 patients in Europe and millions of their caregivers, family members and employers. This NEUROMICS project brings together the leading research groups in Europe, five highly innovative SMEs and relevant oversea experts using the most sophisticated Omics ...
Voir le projet

 20

 TERMINÉ 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet

 38

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

IMAging GEnetics for MENtal Disorders (IMAGEMEND)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. I ...
Voir le projet

 15

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet

 29

 TERMINÉ 

BBMRI - Large Prospective Cohorts (BBMRI-LPC)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,

In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinarity and scale advantage. This has yielded valuable insights and some led to new and better medicines and treatments for diseases. However, disease-focused studies provide less insight in the real disease onset, the relative disease burden in the population, an ...
Voir le projet

 36

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 

Towards Early diagnosis and biomarker validation in Arthritis Management (EURO-TEAM)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early ...
Voir le projet

 17

 TERMINÉ 

Genetic studies of pre-eclampsia in Central Asian and European populations (INTERPREGGEN)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,

Pre-eclampsia, one of the most dangerous cardiometabolic complications of pregnancy, claims the lives of 50,000 mothers and almost one million babies annually. Pre-eclampsia and other hypertensive disorders of pregnancy remain the second most common cause of maternal death. The incidence of pre-eclampsia in Central Asian countries is over twice as high as in western Europe. Inter-population differ ...
Voir le projet

 13

 TERMINÉ 

Interdisciplinary training network for Tourette Syndrome; structuring European Training capacities for neurodevelopmental disorders (TS-EUROTRAIN)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

There is a striking lack in structured and standardized training infrastructure for neurodevelopmental disorders across Europe. Such training will be fundamental to promoting standards of care across Europe and will ultimately lead to strategies for the promotion of childhood mental health in Europe. The focus of this Initial Training Network (ITN) is Gilles de la Tourette Syndrome (TS), an inheri ...
Voir le projet

 12

 TERMINÉ 

European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity (EuroTARGET)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical ...
Voir le projet

 15

 TERMINÉ 

Psychiatric Diagnostic and Prevention Consortium (PSYCHDPC)

Date du début: 1 janv. 2012, Date de fin: 31 juil. 2016,

PsychDPC contains leading European centres in genetics and psychiatry, richly endowed with expertise in both clinical and basic research. The partners bring together state-of-the-art technical facilities, high academic standards as well as established training activities, which will be utilized in concert to maximise the outcome of the project. The primary aim of PsychDPC is to translate data emer ...
Voir le projet

 6

 TERMINÉ 

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Voir le projet

 15

 TERMINÉ 

A European Initial Training Network on the History, Archaeology, and New Genetics of the Trans-Atlantic Slave Trade (EUROTAST)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The principal aim of this ITN is to examine the history of the transatlantic slave trade and its legacies from a variety of different angles. The idea is to hire thirteen Early Stage Researchers (ESRs) and two Experienced Researchers (ERs) across Europe and a wide range of disciplines, including history, archaeology, sociology, heritage studies and genetics, to investigate various aspects of the s ...
Voir le projet

 10

 TERMINÉ 

Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia (CRESTAR)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to b ...
Voir le projet

 11

 TERMINÉ 

Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)

Date du début: 1 sept. 2009, Date de fin: 28 févr. 2015,

Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Voir le projet

 20

 TERMINÉ 

Next generation disease mapping (NextGene)

Date du début: 1 oct. 2010, Date de fin: 31 déc. 2014,

During the last few years, most major disease phenotypes have been studied through genome-wide association mapping. This has been a remarkably successful enterprise, resulting in the discovery of more than 500 validated SNP-phenotype associations. Yet, these associations do not explain all the heritability of many common genetic diseases and it is not at all clear how they exert their effect at th ...
Voir le projet

 2

 TERMINÉ 

Genotype-To-Phenotype Databases: A Holistic Solution (GEN2PHEN)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2013,

"The GEN2PHEN project aims to unify human and model organism genetic variation databases towards increasingly holistic views into Genotype-To-Phenotype (G2P) data, and to link this system into other biomedical knowledge sources via genome browser functionality. The project will establish the technological building-blocks needed for the evolution of today’s diverse G2P databases into a future seaml ...
Voir le projet

 23

 TERMINÉ 

Translational Research in Europe – Applied Technologies for Osteoarthritis (TREAT OA)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2013,

TREAT-OA will address the need for better treatment and diagnostics for osteoarthritis (OA) - the most common cause of disability in Europe. Currently there are no drugs that can cure, reverse or halt the disease. Nor are there yet reliable clinical biochemical markers for diagnosis or prognosis which is an impediment to the management of OA, costs of therapeutic trials and the development of dise ...
Voir le projet

 11

 TERMINÉ 

IAPP on novel genetic and phenotypic markers of Parkinson's disease and Essential Tremor (MarkMD)

Date du début: 1 mars 2009, Date de fin: 28 févr. 2013,

Copy number variations (CNV) are ubiquitously found throughout in the human genome. Their role in monogenic as well as multifactorial disorders as potential disease modifier is more and more stressed (Abecasis et al., 2007). In order to investigate the role of CNV in Parkinson’s disease (PD) and Essential Tremor (ET), two frequent neurological diseases, MARKMD brings together the unique expertises ...
Voir le projet

 2

 TERMINÉ 

Comparative Genomics and Next Generation Sequencing (COGANGS)

Date du début: 1 nov. 2010, Date de fin: 28 févr. 2013,

"The activity of genes is absolutely essential for all life – from viruses and bacteria to crops and human beings. Despite the many technological breakthroughs within life science research during the last 20-30 years, we are however still far away from fully understanding the activity of genes and which factor influence (regulates) the gene activity. Such knowledge is, by nature, of very high impo ...
Voir le projet

 6

 TERMINÉ 

Genetic prostate cancer variants as biomarkers of disease progression (PROMARK)

Date du début: 1 janv. 2008, Date de fin: 31 déc. 2012,

Prostate cancer is the most common cancer in males in Europe, causing over 87,000 deaths in 2006. Early diagnosis and treatment are key factors in determining survival but screening methods based on the commonly-used PSA blood test have low specificity and result in excessive treatment of localized lesions that might never progress to symptomatic cancer. Biomarkers that help determine which of the ...
Voir le projet

 6

 TERMINÉ 

European Network for Genetic and Genomic Epidemiology (ENGAGE)

Date du début: 1 janv. 2008, Date de fin: 31 déc. 2012,

"ENGAGE (European Network for Genetic and Genomic Epidemiology) has, as its central objective, the translation of the wealth of data emerging from large-scale research efforts in molecular epidemiology into information of direct relevance to future advances in clinical medicine. ENGAGE will do this through the integration of very large-scale genetic and phenotypic data already available from a sub ...
Voir le projet

 26

 TERMINÉ 

GENETIC FACTORS FOR OSTEOPOROSIS (GEFOS)

Date du début: 1 mars 2008, Date de fin: 31 août 2012,

"Osteoporosis is a common, age-related disease with a strong genetic component. With increasing age of the population, Europe and industrialised countries across the globe are facing a substantial increase in osteoporotic fractures, which account for considerable disease-burden and costs. Early identification and treatment of subjects at risk can help preventing this, and genetic susceptibility al ...
Voir le projet

 11

 TERMINÉ 

A comprehensive dissection of pneumococcal-host interactions (PNEUMOPATH)

Date du début: 1 mars 2009, Date de fin: 31 août 2012,

"This project is a fundamental, comprehensive study of the host-pathogen interactions during infection with Streptococcus pneumoniae. The expectation is that the basic knowledge gained from this work will give new targets for vaccination, diagnosis and treatment. In PNEUMOPATH, academic and industrial partners will work together in six scientific workpackages. 1) The molecular epidemiology of anti ...
Voir le projet

 15

 TERMINÉ 

Fighting Aneurysmal Diseases (FAD)

Date du début: 1 juil. 2008, Date de fin: 30 juin 2012,

"Fighting Aneurysmal Diseases (FAD) is a public health in EU, because of the ageing population. In the absence of intervention, aneurysms evolve towards rupture and death. The translational objectives of the project are to accelerate the acquisition of knowledge, and to develop new diagnostic and therapeutic tools for FAD in humans. The project innovates by integrating two different localizations ...
Voir le projet

 15

 TERMINÉ 

Copy number variations conferring risk of psychiatric disorders in children (PsychCNVs)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2012,

The recent technical improvements for the study of the cytogenetic basis of disease have led to the identification of many microdeletion and microduplication syndromes. De novo copy number variants (CNVs) are seen more often than expected in autistic patients, and rare chromosomal aberrations are known to account for a small fraction of schizophrenia and bipolar disorder. Recurrent spontaneous mut ...
Voir le projet

 8

 TERMINÉ 

Copy Number Variation and Endophenotypes in Psychiatric Disorders (PsychGene)

Date du début: 1 mars 2008, Date de fin: 29 févr. 2012,

A genome-wide copy number variant (CNV) association study for schizophrenia (SZ), bipolar disorder (BP) and major depression (MD) will be conducted at deCODE genetics using a discovery sample of 2400 affected (800 SZ, 600 BP, 1,000 MD) and 20,000 controls. CNV data will be generated from the newly released HumanCNV370-Duo array designed by deCODE genetics and Illumina. In this array there are abou ...
Voir le projet

 3

 TERMINÉ 

Identification and functional characterization of genetic cancer risk variants (CancerGene)

Date du début: 1 mars 2008, Date de fin: 29 févr. 2012,

This Industry-Academia Partnership and Pathways (IAPP) joins three groups which have hitherto focused on different aspects of cancer genetics. deCODE genetics (deCODE) has recently identified several genetic risk variants that are associated with increased risk of cancer, including two distinct genetic prostate cancer risk variants on chromosome 8q24. The University of Torino (UNITO) group has id ...
Voir le projet

 3

 TERMINÉ 

Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)

Date du début: 1 févr. 2008, Date de fin: 31 janv. 2011,

The Preparatory Phase for a pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) will focus on technical, legal, governance, and financial issues to • prepare to construct BBMRI, building on existing biobanks, resources and technologies, specifically complemented with innovative components and properly embedded into European scientific, ethical, legal and societal fra ...
Voir le projet

 55